Company intelligence / Profile preview
American Gene Technologies
Rockville, Maryland, United Statesamericangene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
AGT’s lead program AGT103-T completed a Phase Ia trial in HIV with no serious adverse events and evidence of engraftment and persistence of modified T cells. The company has launched Addimmune as a subsidiary to advance the HIV cure into Phase Ib trials. Other programs are at preclinical or early clinical stages.[6][8][10]
- Therapeutic areas
- OncologyMetabolic DisordersInfectious Diseases
- Modalities
- Autologous cell therapy (genetically modified T cells)Lentiviral vector-based gene therapy[1][7][9]
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Collaborations with NIAID on peer-reviewed research articles [4], but no major pharma partnerships disclosed.
Beyond the preview
Go deeper on American Gene Technologies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on American Gene Technologies.